Renal Denervation Market to Witness Increased Incremental Dollar Opportunity During the Forecast Period


FDA Approvals to Foster Demand Growth: Regulatory approvals are becoming a necessary aspect for effective business for the providers of renal denervation offerings. The US Food & Drug Administration (FDA) approval for use of renal denervation systems is a key milestone for the renal denervation market participants. The companies are seeking approval for their renal denervation systems and devices for their use in clinical trials. Medtronic, a leading renal denervation market player announced the FDA approval a clinical trial of the company’s Symplicity Spyral renal denervation system in patients on high blood pressure medications.

Continual Clinical Trials in Emerging Nations to Reflect Future Opportunities for Market Players: The increasing clinical trials for the treatment for disorders such as hypertension and blood pressure are a major influencing factor for the renal denervation market. This rise in trials is expected to boost the consumption of renal denervation thereby offering promising opportunities for market players. Emerging clinical trials in leading economies such as Europe and the United States are expected to provide scope of development. For instance, Stanford Health, is pioneering the ongoing RADIANCE-HTN study in Connecticut. The international and multicenter trial is connected at various centers located in Europe and the United States. The aim of the study is to examine and investigate the capabilities of endovascular ultrasound-based renal denervation for reducing blood pressure in patients with treatment resistant hypertension or moderate or mild hypertension. The initial data reflected a significant decrease in blood pressure. Stanford recognizes the need for this trial as hypertension affects 1 out of 3 adults in America.

New Capabilities of Renal Denervation: Renal Denervation incorporated with ultrasound technology are capable of overcoming the limitations of radiofrequency based renal denervation system. The high-frequency sounds waves of the ultrasound energy help in ablating the nerves, without coming in direct contact with the tissues. This helps in reducing renal arteries injuries. According to a clinical trial RADIOSOUND-HTN, presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, the ultrasound based ablation of renal arteries reflected superiority over multipolar radiofrequency based ablation, according to investigators. Ultrasound renal denervation system are gaining major emphasis which is greatly supported by the approvals from regulatory bodies. ReCor medical, for instance, recently announced the approval of Investigational Device Exemption (IDE) for its new pivotal study of Paradise Ultrasound Denervation System for treating hypertension by the FDA.

Competitive Landscape helps in Examining Strategies Adopted by Prominent Players: The prominent players in the renal denervation market are constantly working towards developing a robust systems which could incorporate renal denervation for reducing the challenges related to blood pressure and hypertension. Clinical trials are increasingly being carried out to uplift the capabilities of renal denervation. The key players that contribute to the overall renal denervation market include Medtronic PLC, Symple Surgical, Inc., Cardiosonic, Inc., Boston Scientific Corp., Kona Medical, Inc., ReCor Medical, Inc., Abbott Laboratories, Mercator MedSystems, Inc., Ablative Solutions, Inc., and Renal Dynamics.

Request Report Sample@

Some Developments Carried Out by Renal Denervation Market Players: Otsuka Holdings acquired ReCor Medical, Inc., reflecting a significant step in future for the company’s medical device business, by harnessing an innovative technology with the expertise of Otsuka in clinical and pharmaceuticals development, as stated by the company president.


Please enter your comment!
Please enter your name here